Cxcr4 - C-X-C motif chemokine receptor 4 Gene

Rattus norvegicus

Gene ID: 60628 | Gene type: protein coding

About Cxcr4

Primary_assembly 13: 40,077,976-40,081,883 reverse strand.mRatBN7.2:CM026986.1

This gene has 1 transcript (splice variant), 285 orthologues, 24 paralogues and is associated with 54 phenotypes. Biased expression in Thymus (RPKM 542.4), Lung (RPKM 351.9) and 8 other tissues.

Summary

Enables small molecule binding activity. Involved in several processes, including detection of stimulus involved in sensory perception of pain; endothelium development; and nervous system development. Located in endosome; nucleus; and plasma membrane. Used to study pulmonary hypertension and temporal lobe epilepsy. Human ortholog(s) of this gene implicated in WHIM syndrome; hematologic Cancer (multiple); leukopenia; osteoporosis; and pancreatic adenocarcinoma. Orthologous to human CXCR4 (C-X-C motif Chemokine Receptor 4). [provided by Alliance of Genome Resources, Apr 2022]

Cxcr4 Products(1)

mRNA	Protein	Name
NM_022205.3	NP_071541.2	C-X-C chemokine receptor type 4

Cxcr4 Protein Structure

CXCR4_N

7tmA_CXCR4

0
100
200
300
349 a.a.

Protein Preferred Names

Protein Names

C-X-C chemokine receptor type 4

CXC chemokine receptor	CXC-R4
CXCR-4	LESTR
SDF-1 receptor	chemokine (C-X-C motif) receptor 4
chemokine receptor (LCR1)	fusin
leukocyte-derived seven transmembrane domain receptor	stromal cell-derived factor 1 receptor

Related Agents

Approval

Bioactive Molecules (2)

Cat. No.	Product Name	Effect	Purity	Rare Diseases
HY-10046	Plerixafor	Antagonist	98.61%	Yes
HY-50912	Plerixafor octahydrochloride	Antagonist	≥98.0%	Yes

Clinical Phase

Bioactive Molecules (9)

Cat. No.	Product Name	Effect	Purity	Phase
HY-P0171	Motixafortide	Antagonist	99.88%	Phase 3
HY-50101A	Mavorixafor trihydrochloride	Antagonist	98.69%	Phase 3
HY-P1682A	Balixafortide TFA	Antagonist	99.78%	Phase 3
HY-50101	Mavorixafor	Antagonist	/	Phase 3
HY-P1682	Balixafortide	Antagonist	/	Phase 3
HY-12488	LY2510924	Inhibitor	99.73%	Phase 2
HY-19867A	Burixafor hydrobromide	Antagonist	≥98.0%	Phase 2
HY-114244	USL311	Antagonist	99.97%	Phase 2
HY-13696	MSX-122	Antagonist	98.92%	Phase 1

Inhibitory Antibodies (1)

Cat. No.	Product Name	Effect	Purity	Phase
HY-P99272	Ulocuplumab	Antagonist	99.90%	Phase 3

Pre-clinical Phase

Bioactive Molecules (36)

Cat. No.	Product Name	Effect	Purity	Rare Diseases
HY-N0011	Baohuoside I	Inhibitor	99.96%	Unkown
HY-111793A	NUCC-390 dihydrochloride	Agonist	99.05%	Unkown
HY-101458A	IT1t dihydrochloride	Antagonist	99.89%	Unkown
HY-15478	WZ811	Antagonist	≥98.0%	Unkown
HY-P1102	TC14012	Modulator	99.90%	Unkown
HY-P1104A	FC131 TFA	Antagonist	99.89%	Unkown
HY-15971	AMD 3465 hexahydrobromide	Antagonist	≥98.0%	Unkown
HY-P7061A	ALX 40-4C Trifluoroacetate	Inhibitor	96.16%	Unkown
HY-P1103	CTCE-9908	Antagonist	99.69%	Unkown
HY-112709	LIT-927		99.86%	Unkown
HY-103009	MSX-127	Antagonist	99.68%	Unkown
HY-103010	MSX-130	Antagonist	98.00%	Unkown
HY-15971A	AMD 3465	Antagonist	/	Unkown
HY-101458	IT1t	Antagonist	/	Unkown
HY-P1104	FC131	Antagonist	/	Unkown
HY-122058A	KRH-3955 hydrochloride	Antagonist	/	Unkown
HY-111793	NUCC-390	Agonist	/	Unkown
HY-P3612	CTCE-0214	Agonist	98.94%	Unkown
HY-P7061	ALX 40-4C	Inhibitor	/	Unkown
HY-146053	CXCR4 modulator-1	Modulator	/	Unkown
HY-136437	CXCR4 antagonist 1	Antagonist	/	Unkown
HY-129094	ICT5040	Antagonist	/	Unkown
HY-115493	TIQ-15	Antagonist	/	Unkown
HY-P4111	Peptide R	Antagonist	/	Unkown
HY-147808	CXCR4 antagonist 7	Antagonist	/	Unkown
HY-146413	HF50731	Antagonist	/	Unkown
HY-147979	CXCR4 antagonist 9	Antagonist	/	Unkown
HY-146372	CXCR4 antagonist 5	Antagonist	/	Unkown
HY-P1102A	TC14012 TFA	Modulator	/	Unkown
HY-P1103A	CTCE-9908 TFA	Antagonist	/	Unkown
HY-147978	CXCR4 antagonist 8	Antagonist	/	Unkown
HY-146401	CXCR4 antagonist 6	Antagonist	/	Unkown
HY-146054	CXCR4 modulator-2	Modulator	/	Unkown
HY-P0172	ATI-2341	Agonist	/	Unkown
HY-144285	CXCR4 antagonist 4	Antagonist	/	Unkown
HY-144286	CXCR4 antagonist 3	Inhibitor	/	Unkown

Orthologs Information

Species	Symbol	Source	ID
Homo sapiens	Cxcr4	NCBI	NCBI:7852

Name
Email *

	Sorry, but the email address you supplied was invalid.